NDAQ:MBRX - Post Discussion
Post by
whytestocks on Jan 24, 2024 2:00pm
Moleculin Announces 2023 Year-End Annamycin Clinical Trials
News; $MBRX Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 PR Newswire – MB-106 AML Phase 1B /2 trial (MB-106) preliminary data readout: Reached 67% recruitment ...
MBRX - Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
Be the first to comment on this post